Federal watchdog seeks public’s opinion on how to protect Canadians from excessively priced patented

From: Patented Medicine Prices Review Board Canada

The Patented Medicine Prices Review Board (PMPRB) released its new draft Guidelines today and launched a 60-day consultation period with stakeholders and interested members of the public. This consultation follows Health Canada’s recent amendments to the Patented Medicines Regulations, which strengthen and modernize Canada’s pricing framework for patented drugs so that the PMPRB can better protect Canadian consumers from excessive prices in an era marked by increasingly high cost drugs.

The Guidelines explain the steps taken by staff at the PMPRB in assessing whether a patented drug appears to be priced excessively in Canada. It also explains what information patent-holding pharmaceutical companies must provide to the PMPRB to enable it to make that assessment.

/Public Release. View in full here.